Sundry Photography / Shutterstock.com
18 October 2022Big PharmaCatherine Wycherley
Gilead inks deal for cancer-beating antibody
Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
23 August 2022 Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Big Pharma
4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.
Big Pharma
7 March 2023 The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.
Editor's picks
Editor's picks
Americas
23 August 2022 Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Big Pharma
4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.
Big Pharma
7 March 2023 The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.
Americas
23 August 2022 Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Big Pharma
4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.
Big Pharma
7 March 2023 The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.